美泊利珠单抗在嗜酸性粒细胞疾病中的应用。
Mepolizumab in eosinophilic disorders.
机构信息
Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML2010, Cincinnati, OH 45229-3039, USA.
出版信息
Expert Rev Clin Immunol. 2011 Jul;7(4):411-7. doi: 10.1586/eci.11.27.
Abstract
Mepolizumab (Bosatria(®), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 κ type, which targets human IL-5 and thus prevents its interaction with the α-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders.
摘要
美泊利珠单抗（Bosatria(®)，葛兰素史克）是一种生物制剂，用于治疗哮喘。它是一种人源化 IgG1 κ 单克隆抗体，靶向人白细胞介素 5（IL-5），从而阻止其与 IL-5 受体的 α 链相互作用。迄今为止，它尚未被批准用于任何与嗜酸性粒细胞相关的疾病；然而，一些研究表明，它在一系列与嗜酸性粒细胞相关的疾病中具有一定的治疗益处。本文评估了美泊利珠单抗目前可用的临床前和临床研究，以及其对各种嗜酸性粒细胞疾病的治疗作用。
相似文献
1
Mepolizumab in eosinophilic disorders.美泊利珠单抗在嗜酸性粒细胞疾病中的应用。
Expert Rev Clin Immunol. 2011 Jul;7(4):411-7. doi: 10.1586/eci.11.27.
2
Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.美泊利单抗：240563，抗白细胞介素-5单克隆抗体 - 葛兰素史克公司，抗白细胞介素-5单克隆抗体 - 葛兰素史克公司，SB 240563
Drugs R D. 2008;9(2):125-30. doi: 10.2165/00126839-200809020-00006.
3
Mepolizumab and eosinophil-mediated disease.美泊利珠单抗与嗜酸性粒细胞相关疾病
Curr Med Chem. 2009;16(36):4774-8. doi: 10.2174/092986709789909639.
4
Current update on eosinophilic lung diseases and anti-IL-5 treatment.嗜酸性粒细胞性肺疾病与抗白细胞介素-5治疗的最新进展
Recent Pat Antiinfect Drug Discov. 2011 Sep 1;6(3):189-205. doi: 10.2174/157489111796887855.
5
A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.抗白细胞介素 5 单克隆抗体美泊利珠单抗治疗高嗜酸性粒细胞综合征和哮喘的综述。
J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048.
6
[Anti-interleukin-5 therapy for eosinophilic diseases].[抗白细胞介素-5疗法治疗嗜酸性粒细胞疾病]
Hautarzt. 2007 Feb;58(2):122, 124-7. doi: 10.1007/s00105-006-1273-x.
7
Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.在过敏性炎症、嗜酸性粒细胞增多症和癌症中利用人类嗜酸性粒细胞的治疗策略。
Curr Allergy Asthma Rep. 2012 Oct;12(5):402-12. doi: 10.1007/s11882-012-0290-3.
8
Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.美泊利珠单抗（一种抗白细胞介素-5 单克隆抗体）的药代动力学和药效学。
Clin Pharmacokinet. 2011 Apr;50(4):215-27. doi: 10.2165/11584340-000000000-00000.
9
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.抗白细胞介素-5（美泊利珠单抗）治疗高嗜酸性粒细胞综合征
J Allergy Clin Immunol. 2004 Jan;113(1):115-9. doi: 10.1016/j.jaci.2003.10.049. Epub 2003 Dec 12.
10
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.美泊利珠单抗作为淋巴细胞变异型高嗜酸性粒细胞综合征的皮质类固醇节约剂。
J Allergy Clin Immunol. 2010 Oct;126(4):828-835.e3. doi: 10.1016/j.jaci.2010.06.049.
引用本文的文献
1
Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies.囊性纤维化的分子靶点及单克隆抗体的治疗潜力
Saudi Pharm J. 2022 Dec;30(12):1736-1747. doi: 10.1016/j.jsps.2022.10.002. Epub 2022 Oct 8.
2
Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series.美泊利单抗不能预防阿司匹林加重性呼吸系统疾病患者的所有阿司匹林诱发反应：病例系列报道
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1384-1385. doi: 10.1016/j.jaip.2020.09.007. Epub 2020 Sep 19.
3
Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series.美泊利单抗在成年嗜酸性粒细胞表型囊性纤维化患者中的应用：病例系列
Allergy Asthma Clin Immunol. 2020 Jan 6;16:3. doi: 10.1186/s13223-019-0397-3. eCollection 2020.
4
Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma.托法替尼治疗哮喘的制剂前研究与评价。
AAPS PharmSciTech. 2019 Apr 16;20(5):167. doi: 10.1208/s12249-019-1377-0.
5
MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABA receptors without causing systemic immune suppression.MIDD0301 - 一种新型抗炎性哮喘药物，靶向 GABA 受体而不引起全身免疫抑制。
Basic Clin Pharmacol Toxicol. 2019 Jul;125(1):75-84. doi: 10.1111/bcpt.13206. Epub 2019 Feb 21.
6
Type 2 immunity in asthma.哮喘中的2型免疫
World Allergy Organ J. 2018 Jun 26;11(1):13. doi: 10.1186/s40413-018-0192-5. eCollection 2018.
7
The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.人类病毒挑战模型：加速呼吸道抗病毒药物、疫苗和新型诊断方法的评估。
Respir Res. 2018 Jun 22;19(1):123. doi: 10.1186/s12931-018-0784-1.
8
A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABA Receptors in the Lung.一种新型口服哮喘药物候选物，通过靶向肺部的 GABA 受体减少平滑肌收缩和炎症。
Mol Pharm. 2018 May 7;15(5):1766-1777. doi: 10.1021/acs.molpharmaceut.7b01013. Epub 2018 Apr 2.
9
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.重度嗜酸性粒细胞性哮喘：从白细胞介素-5的致病作用到美泊利珠单抗的治疗作用
Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017.
10
Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.新单克隆抗体治疗严重哮喘的重叠作用。
Drugs. 2017 Oct;77(16):1769-1787. doi: 10.1007/s40265-017-0810-5.
本文引用的文献
1
Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.美泊利珠单抗（一种抗白细胞介素-5 单克隆抗体）的药代动力学和药效学。
Clin Pharmacokinet. 2011 Apr;50(4):215-27. doi: 10.2165/11584340-000000000-00000.
2
Clinical manifestations and treatment of Churg-Strauss syndrome.变应性肉芽肿性血管炎的临床表现和治疗。
Rheum Dis Clin North Am. 2010 Aug;36(3):527-43. doi: 10.1016/j.rdc.2010.05.003. Epub 2010 Jun 20.
3
Involvement of mast cells in eosinophilic esophagitis.肥大细胞在嗜酸性粒细胞性食管炎中的作用。
J Allergy Clin Immunol. 2010 Jul;126(1):140-9. doi: 10.1016/j.jaci.2010.04.009. Epub 2010 Jun 9.
4
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.美泊利珠单抗作为变应性肉芽肿性血管炎患者的一种类固醇节省治疗选择。
J Allergy Clin Immunol. 2010 Jun;125(6):1336-43. doi: 10.1016/j.jaci.2010.03.028.
5
A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.抗白细胞介素 5 单克隆抗体美泊利珠单抗治疗高嗜酸性粒细胞综合征和哮喘的综述。
J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048.
6
Sustained response to mepolizumab in refractory Churg-Strauss syndrome.难治性变应性肉芽肿性血管炎对美泊利单抗的持续反应。
J Allergy Clin Immunol. 2010 Jan;125(1):267-70. doi: 10.1016/j.jaci.2009.10.014.
7
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.抗白细胞介素-5 抗体治疗（美泊利单抗）治疗活动性嗜酸性食管炎：一项随机、安慰剂对照、双盲试验。
Gut. 2010 Jan;59(1):21-30. doi: 10.1136/gut.2009.178558.
8
Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis.嗜酸细胞性食管炎中食管黏膜局部 B 细胞与 IgE 的产生。
Gut. 2010 Jan;59(1):12-20. doi: 10.1136/gut.2009.178020.
9
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.美泊利单抗用于治疗伴有痰液嗜酸性粒细胞增多的泼尼松依赖型哮喘。
N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.
10
Mepolizumab and exacerbations of refractory eosinophilic asthma.美泊利珠单抗与难治性嗜酸性粒细胞性哮喘的病情加重
N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991.
Zotero 插件